A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

NCT03987919 on ClinicalTrials.gov · last registry update 2022-02-14

An unusually large phase 3: 1,879 participants, more than double the 424 typical for the stage. The sponsor logged completion for 28 January 2021. Primary outcome, as filed: Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg). semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 1,879
Started: 2019-07-30
Primary completion: 2021-01-28 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.